SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (4887)7/17/1998 10:46:00 PM
From: John Metcalf  Read Replies (1) of 6136
 
Margie, thanks for the abstracts on immune CD4 cell reconstitution. I found this especially meaningful, though it has been suggested for years (by the Ritonivir lymph studies, for example):

{Could it be that compartmentation of both cell types and anatomical locations are occurring in terms of exposure of HIV to the components of a combination? If 3TC is the only drug active in certain cell types or locations, then these reservoirs of HIV are effectively receiving monotherapy with that compound leading to rapid resistance.}

You have provided an in-depth explanation of Rick's point after the Geneva Conference: patients will not stop PI's in favor of treatment that attacks a single target (reverse transcriptase). There is differential localization and activity of various drugs.

Though it is painfully obvious, perhaps it bears repeating that no monotherapy is recommended. Sustiva will be good for Viracept users, and vice-versa, whether they are both sold by DuPont's sales force or not.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News